Catalog No.
DHD47901
Description
Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to 2b Isoform of thefibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cellmediated cytotoxicity.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P21802
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
FPA144 ,FPA-144, FPA114-A, CAS: 1952272-74-0
Clone ID
Bemarituzumab
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design, PMID: 31094225
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma, PMID: 32220925
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma, PMID: 32167861
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial, PMID: 32965540
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials, PMID: 34383128
FGFR Inhibitor Stymies Gastric Cancer, PMID: 33574117
Advances in the treatment of gastric cancer: 2020-2021, PMID: 34456227
The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration, PMID: 34398359
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma., PMID:40513139
Advancing Ocular Safety Profile Assessment: A Novel Grading Scale for Ocular Adverse Reactions Associated with Bemarituzumab., PMID:40355729
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer., PMID:40216702
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art., PMID:39315517
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis., PMID:38861192
New therapeutic target molecules for gastric and gastroesophageal junction cancer., PMID:38630383
Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2., PMID:38485551
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions., PMID:38424198
Advances in targeted therapy for gastric cancer based on tumor driver genes., PMID:38413217
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial., PMID:38308771
Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer., PMID:37951282
[Oesogastric cancer - new therapeutic targets]., PMID:36371284
Bemarituzumab enters the FIGHT., PMID:36323931
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study., PMID:36244398
Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments., PMID:36238135
The dawn of precision medicine in diffuse-type gastric cancer., PMID:35281349
FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?, PMID:35054474
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer., PMID:34719330
Advances in the treatment of gastric cancer: 2020-2021., PMID:34456227
The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration., PMID:34398359
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials., PMID:34383128
FGFR Inhibitor Stymies Gastric Cancer., PMID:33574117
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial., PMID:32965540
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma., PMID:32220925
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma., PMID:32167861
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design., PMID:31094225
For research use only. Not for human or drug use.
